GenIP PLCLSE: GNIP

GenIP: Commercial Update

· Issued by GenIP PLC via RNS

Summary by 6ix AI

GenIP plc, a provider of AI-driven services that help research organisations and corporations commercialise their innovations, said several customers have trialled its Invention Evaluator Platform in a soft launch. It said the full commercial launch of the subscription-based platform remains on track for December 2026.

Key details

  • During the trial GenIP identified 17 pilot accounts across several international markets and has begun initial talks about moving them to the new platform. One customer from 2025 has agreed to start a migration plan as an early adopter.
  • Management believes the pilot accounts alone could represent a potential annual subscription value of around US$170,000 in aggregate.
  • After the full launch, GenIP intends to offer its historical base of approximately 300 customers a move to the subscription model. Management estimates a global total addressable market (the overall potential market) of approximately US$50million per annum for the platform, before additional services.
  • Separately from the new platform, GenIP has secured orders for its existing services, including from universities in Chile and Brazil, a Brazilian technology company and a Spanish university-industry collaboration network. After appointing a sales representative in Chile, it gained three new customers and reactivated two across South America.
  • Management estimates a sales pipeline of approximately US$1.0 million, including opportunities with organisations associated with Saudi Aramco and proposal discussions with Amazon Web Services (AWS) in Brazil.

What’s still pending

  • GenIP says the full commercial launch of the subscription platform remains on track for December 2026, and that securing its first paid platform subscriptions is an immediate priority.
  • Talks about moving the 17 pilot accounts to the platform are at an initial stage.
  • The US$170,000 potential subscription value, the US$50million addressable market estimate and the US$1.0 million pipeline are management estimates, not contracted annual recurring revenue or a revenue forecast.
  • The Board says it remains confident the business will continue to trade in line with management expectations for the rest of 2026 and reduce cash burn by approximately 40% in 2027.

6ix AI wrote this summary from the release below and checked it against the release.

GenIP PLC
17 November 2026

GenIP plc

("GenIP" or the "Company")

Commercial Update

GenIP plc (AIM: GNIP), a provider of AI-driven services to help research organisations and corporations commercialise their innovations, provides an update on the soft launch of its Invention Evaluator Platform (the “Platform”) as announced on the 19 October 2026.

Successful Soft Launch

Several customers have now successfully trialled the Platform and initial feedback has been positive, with customers preferring the Platform’s new features and its streamlined, action-oriented approach to managing and prioritising technologies.

During the trial, the Company identified 17 pilot accounts across several international markets and has already begun initial commercial discussions about migrating them to the new Platform including a significant customer from 2025, who has already agreed to initiate the migration plan as an early adopter.

Based on this early feedback, management believes the pilot accounts alone could represent a potential annual subscription value of around US$170,000 in aggregate*.

Full Commercial Launch Remains on Track

The full commercial launch of the subscription-based Invention Evaluation Platform remains on track for December 2026.

Following the full commercial launch, the Company intends to target its historical customer base of approximately 300 customers presenting them the migration path to the subscription model.

Given the early feedback and ongoing customer conversations, management now estimates a global total addressable market of approximately US$50million per annum*, before additional services, for the new subscription Invention Evaluation Platform.

Continued commercial progress and sales pipeline

GenIP continues to secure orders for its existing services from new and existing customers, including universities in Chile and Brazil, a Brazilian technology company and a Spanish university-industry collaboration network:

  • Following the appointment of a sales representative in Chile, GenIP has secured three new customers and reactivated two historical customer relationships across South America.
  • Increased broader client adoption and repeat usage across academia, government innovation bodies and corporate Research and Development departments, diversifying and strengthening the customer base.
  • Expanded commercial coverage across Asia and Latin America through regional business development appointments.

There is also growing engagement from commercial and corporate customers, including opportunities with organisations associated with Saudi Aramco and several advanced proposal discussions with Amazon Web Services (AWS) in Brazil.

In aggregate, management estimate these potential customers represent a sales pipeline of approximately US$1.0 million*.

Outlook

GenIP is entering a new commercial phase, with early positive interest from customers for the Invention Evaluator Platform with its more efficient operating model.

The Company’s immediate priorities are now to convert the significant and increasing sales pipeline into confirmed orders, secure its first paid platform subscriptions and demonstrate improved delivery margins.

The Board therefore remains confident the business will continue to trade in-line with management expectations for the remainder of 2026 and reduce cash burn by approximately 40% in 2027, as the businesses transitions onto a stronger foundation with significant levels of recurring revenue.

* Potential value is not contracted ARR or a revenue forecast.

GenIP plc

Melissa Cruz, CEO

Via Walbrook PR

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish / Asia Szusciak / Andrew Price

Tel: +44 (0) 20 7628 3396

AlbR Capital Limited (Joint Broker)

Colin Rowbury / Jon Belliss

Tel: +44 (0) 20 7399 9427

cr@albrcapital.com / Jb@albrcapital.com

Walbrook PR (Financial PR)

Alice Woodings

William Turner

GenIP@walbrookpr.com

Tel: +44 (0) 7407 804 654

Tel: +44 (0) 7407 020 470

focusIR (Investor Relations)

Kat Perez

Dr Paul Cornelius

GenIP@focusIR.com

Tel: +44 (0) 20 4570 2234

Tel: +44 (0) 20 4570 2246

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

Distribution: This announcement has been notified via a Regulatory Information Service and it is not authorised for distribution into North America or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.

About GenIP

GenIP is a next-generation business at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

Service Offerings

GenIP operates through two synergistic service lines:

Service

Description

Value Proposition

Invention Intelligence Product Suite

AI-powered market intelligence reports assessing the commercial potential of emerging technologies

Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy

IP Commercialisation Services

End-to-end engagement to help research organisations commercialise innovations

Provides cost-effective, broad support to achieve our clients' strategic objectives

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

Vision & Strategy

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

  • Organic Expansion: Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.
  • Service Deepening: Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.
  • Strategic Acquisitions: Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

GenIP PLC on 6ix

Story so far

Earlier from GenIP

Later from GenIP

All GenIP news releases